Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Montfermeil – page 26

3 423 clinical trials in Montfermeil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montfermeil at a glance
3 423
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 423 trials in Montfermeil

Open in trial search

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

A study of daraxonrasib (RMC-6236) compared to observation in patients with resected pancreatic cancer following chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

Homocystinuria

Recruiting

A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegtibatinase
  • Sponsor:Travere Therapeutics Inc.

Sepsis

Recruiting

Study of dexmedetomidine and a drug combination for treating patients on mechanical ventilation with septic shock.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Hospices Civils De Lyon

A study of PM54 and pembrolizumab in adults with advanced cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pharma Mar S.A.

Nephropathy

Recruiting

A study to evaluate the efficacy and safety of obinutuzumab compared to prednisolone in adults with newly onset minimal change disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Medizinische Universitaet Innsbruck

A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness and safety of efaglomograstim alfa in patients with low blood platelet counts caused by chemotherapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rafutrombopag ethanolamine
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NIO752
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Montfermeil

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on acute myocarditis treatment and cardiac arrhythmia management. Research includes evaluation of corticosteroid therapy for improving left ventricular function and investigating preventive measures for premature ventricular complexes.

  • Myocarditis Treatment Optimization
  • Cardiac Function Management
  • Giant Cell Arteritis Studies

These trials aim to enhance treatment outcomes for patients with various cardiac conditions.

02 Respiratory Medicine

Advanced research in severe asthma management, exploring new biological therapies and treatment optimization strategies. Studies focus on comparing different therapeutic approaches for patients with eosinophilic phenotypes.

  • Asthma Biologics Evaluation
  • Treatment Duration Assessment
  • Therapeutic Monitoring

Investigations aim to improve long-term outcomes for patients with severe respiratory conditions.

03 Inflammatory Conditions

Comprehensive studies examining treatments for ulcerative colitis, sarcoidosis, and inflammatory eye conditions. Research includes innovative monitoring approaches and medication optimization.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Treatment Strategies

Focus on improving patient outcomes through targeted therapies and personalized treatment approaches.

04 Rheumatology and Joint Health

Investigating innovative treatments for knee osteoarthritis and gout, particularly in patients with complex medical conditions. Studies explore new interventional procedures and medication alternatives.

  • Joint Disease Management
  • Pain Control Studies
  • Minimally Invasive Treatments

Research aims to enhance quality of life for patients with chronic joint conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.